TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06539182: A Phase 2, Open-label, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of DZD8586 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Sponsor: Dizal Pharmaceuticals · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 155 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,319,000

Rescue Site Savings

+$7,484,400

Unlock Full NCT06539182 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06539182 Rescue Dossier →